IL17A and rheumatoid arthritis: During a longitudinal follow-up of RA patients who received anti-TNF-α therapy, we found that serum IL-17 levels significantly decreased, in parallel with the clinical remission in the responders, whereas increasing IL-17 levels were found in non-responders.